Business Context and Reporting Period
This Form 8-K, dated December 12, 2023, is filed by Chavant Capital Acquisition Corp. (Chavant) regarding its proposed business combination with Mobix Labs, Inc. The transaction involves a merger where Mobix Labs would become a wholly-owned subsidiary of Chavant, with the combined entity retaining the name Mobix Labs, Inc. The filing serves to supplement the previously filed Proxy Statement/Prospectus with critical updates concerning financing conditions and the scheduling of the shareholder vote.
Key Financial Metrics and Liquidity
The filing does not provide specific revenue, profit, or cash flow figures for Mobix Labs or Chavant. However, it highlights critical liquidity thresholds tied to the transaction:
- Minimum Cash Condition: The Business Combination Agreement requires at least $30.0 million in funds to be available at closing, primarily sourced from a Private Investment in Public Equity (PIPE) Subscription Agreement.
- PIPE Funding Status: As of December 12, 2023, the designated PIPE Investor (ACE SO4 Holdings Limited) has indicated it does not expect to provide the required $30.0 million.
- Going Concern Risk: The filing notes that Mobix Labs has previously disclosed substantial doubt regarding its ability to continue as a going concern. A failure to secure the anticipated funding could materially adversely affect the combined company's liquidity and ability to fund operations.
Material Changes and Recent Developments
The primary material change disclosed is the inability to satisfy the Minimum Cash Condition as originally contemplated:
- Financing Shortfall: Chavant believes it will not meet the $30.0 million cash requirement by the Special Meeting date due to the PIPE Investor's inability to commit funds.
- Meeting Adjournment: The Extraordinary General Meeting of shareholders, originally scheduled for December 14, 2023, is expected to be adjourned and reconvened on December 18, 2023, or another date determined by the Chairperson.
- Redemption Deadline Extension: The deadline for shareholders to exercise redemption rights is expected to be extended to 5:00 p.m. Eastern time on December 14, 2023, or a later date set at the time of adjournment.
- Termination Risk: If the Minimum Cash Condition is not satisfied or waived by the "Outside Date" of January 22, 2024, Mobix Labs is permitted to terminate the Business Combination Agreement. Failure to close by this date would force Chavant to liquidate.
Outlook, Risks, and Management Commentary
Management is actively seeking additional financing to enable Mobix Labs to consider waiving the Minimum Cash Condition. However, the PIPE Investor has provided no assurance of future funding.
- Waiver Discretion: Mobix Labs may choose to waive the Minimum Cash Condition to allow the transaction to close with less cash, but it is not obligated to do so. If waived, the combined company would have significantly less cash than anticipated, potentially jeopardizing operations and growth.
- Liquidation Consequence: If the transaction fails to close by January 22, 2024, Chavant must liquidate. In such an event, outstanding warrants will expire worthless, and there will be no distribution to warrant holders.
- Transaction Costs: Transaction costs are largely incurred and are not expected to decrease proportionally with reduced funding, further straining available cash.
Investor Verification Checklist
- Verify the status of the adjourned Special Meeting and the new deadline for redemption rights.
- Confirm whether Mobix Labs has formally agreed to waive the Minimum Cash Condition or if the transaction remains at risk of termination.
- Review the updated Proxy Statement/Prospectus and Prospectus Supplement No. 2 for any new financing commitments.
- Assess the impact of a potential liquidation on the value of Chavant's ordinary shares and warrants.
- Monitor the "Outside Date" of January 22, 2024, as the final deadline for consummating the business combination.